Sponsored by

Poster Number Index
Click on one of the following number ranges below to display a list of posters.
Click the checkbox next to each item to bookmark.

101 – 200 | 201 – 300 | 301 – 400 | 401 – 500 | 501 – 600 | 601 – 700 | 701 – 800
801 – 900 | 901 – 1000 | 1001 – 1100 | 1101 – 1200 | 2001 – 2100 | 2101 – 2200 | 3001 – 3100
3101 – 3200 | 4001 – 4100 | 4101 – 4200 | 5001 – 5100 | 5101 – 5200 | 6001 – 6100 | 6101 – 6152

  [2002] Accuracy of breast ultrasound BI-RADS classification and final pathological assessment of breast lesions submitted to core biopsy or fine needle aspiration of a breast diagnostic referral center in South Brazil.
  [2003] Using custom protein microarrays to identify autoantibody biomarkers for the early detection of breast cancer.
  [2004] CA 27.29 as a tumour marker for risk evaluation and therapy monitoring in patients with primary breast cancer.
  [2007] CDK2 is required for LMW-cyclin E mediated murine mammary tumorigenesis.
  [2011] Development of a breast cancer brain metastases model to study 131I radioablative therapy.
  [2012] Antitumor activity of chemoendocrine therapy in premenopausal (capecitabine [CAP] + tamoxifen [TAM]) and postmenopausal (CAP + letrozole [LET]) human breast cancer [BC] xenograft models.
  [2013] The role of receptor tyrosine kinase and activated PI3K signaling in response/resistance to HER-2 targeted therapy.
  [2014] Role of radiation induced ß1 – integrin expression in trastuzumab resistance in Her-2 positive breast cancer.
  [2015] Ixabepilone plus capecitabine improves progression free survival in patients with metastatic breast cancer resistant to taxanes: a pooled analysis from two phase III trials.
  [2018] Calpain regulates sensitivity to trastuzumab and survival in HER2-positive breast cancer.
  [2019] Tissue inhibitor of metalloproteinases-1 protects the human breast carcinoma cell line MCF-7 S1 against anthracycline-induced cell death by activation of the akt survival pathway.
  [2020] Fine tuning of the Van Nuys prognostic index (VNPI) 2003 by using genomic grade index (GGI): a new tool for ductal carcinoma in situ (DCIS).
  [2022] UCSC cancer genomics browser.
  [2023] High resolution representational oligonucleotide microarray analysis (ROMA) suggests that TOPO2 and HER2 co-amplification is uncommon in human breast cancer.
  [2024] Distinct multiethnic genome-wide alterations in breast cancer using paraffin embedded samples: preliminary analysis.
  [2025] The pattern of metastatic spread among breast cancer sub-types.
  [2026] A comprehensive analysis of nine prognostic signatures reveals the high classification instability in breast cancer.
  [2030] A reduced qRT-PCR-based gene expression signature with prognostic value in early breast cancer.
  [2031] Phosphoproteomic study of breast cancer: high-throughput SH2 screening.
  [2032] Predicting response to RAD001 treatment in post-menopausal women with ER-positive breast cancer using the breast cancer DSA™ research tool (Almac).
  [2033] Prediction of chemotherapy response in breast cancer by using a four-gene panel including osteopontin, activating leukocyte cell adhesion molecule (ALCAM), HER2 and estrogen receptor (ER).
  [2034] Phosphoproteomic study of breast cancer: quantitative analysis of SH2 binding proteins.
  [2035] Transcriptional profiling of patient-matched ER-positive breast cancer tissue from post-menopausal women treated with neoadjuvant RAD001.
  [2037] Differential expression of microfilamental network-associated proteins in circulating leukocytes of patients with benign and malignant breast tumors versus controls as revealed by clinical proteomics: potential application to early and predictive diagnosis.
  [2038] Evaluation of CD83 antigen in the normal mammary epithelium and fibroadenoma human.
  [2039] Genomic and transcriptomic differences between lobular and luminal ductal invasive carcinoma.
  [2040] MicroRNA profiling of triple negative breast cancer: predicting outcome and targets.
  [2041] Differential gene expression associated with estrogen receptor status of breast cancer identified by microarray meta-analysis.
  [2042] Suppression of mesenchymal phenotype in inflammatory breast cancer by EGFR tyrosine kinase inhibitor erlotinib: a novel approach to suppressing metastasis.
  [2045] CXCR4 alters ID family and ITF2B/E2-2/TCF-4 dynamics to confer invasive phenotype to breast cancer cells.
  [2046] Concentrations of plasminogen activator inhibitor type1 (PAI-I) and urokinase-type plasminogen aktivator (uPA) in primary breast cancer (BC) tissue and corresponding axillary lymph node metastasis.
  [2048] Influence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients.
  [2049] Identification of breast cancer metastasis initiation and virulence genes.
  [2050] JNK2 enhances mammary carcinoma cell migration by regulating EPS8 expression and localization.
  [2051] Expression levels of histone deacetylases and acetylation of histone H4 and tubulin associated with breast cancer progression.
  [2052] RANKL plays a role in migration and invasion of the bone-seeking cell line MDA-MB-231-BO2 through human type I collagen by up-regulating MMP1.
  [2053] Isolation and characterization of a highly metastatic hybrid cell line generated between estrogen receptor (ER) negative and ER positive breast cancer cells in mouse bone marrow.
  [2056] A transcriptional regulatory mechanism in invasive breast cancer; role of AIB-1 and PEA-3.
  [2057] Receptor activator of NF-kB (RANK) and RANK ligand protein expression in invasive ductal carcinoma.
  [2058] Upregulation of Fra-1 and Fra-2 in breast cancer cells results in changes in adhesion, migration, invasion and stem cell markers.
  [2059] Alternative suppression strategy for human breast cancer invasion and metastasis: a potential for a new differentiation therapy.
  [2061] EGF-dependent enhancement of invasive ability in squamous cell carcinoma of the breast.
  [2062] Anoikis-resistant MDA-MB-231 cells: characteristics and pathway analysis.
  [2063] Identification of non-catalytic matrix metalloproteinase 1 residues that participate in collagenolysis.
  [2065] Identification of biomarkers associated with metastastic breast cancer to bone by immunohistochemistry on tissue microarrays.
  [2066] Quantitative gene expression analysis using Oncotype DX in ductal carcinoma in situ that is adjacent to invasive ductal carcinoma.
  [2067] Bone-specific alkaline phosphatase (BSAP) and serum N-telopeptide (sNTX) as predictors of bone loss in postmenopausal women with early breast cancer receiving letrozole as adjuvant therapy: a 5-year study (Z-FAST).
  [2068] The use of proximity ligation assay to identify HER2:HER3 heterodimers in early breast cancers.
  [2069] Fluorescence in situ hybridization (FISH) technique by reference centers for HER2 status determination in metastatic breast cancer: quality assurance results of FISH 2002 study.
  [2070] Rapid screening of tissue microarrays for Her-2 FISH testing is a safe, accurate, efficient and economic method enabling provision of an entirely FISH-based Her-2 testing service.
  [2072] Prognosis in hereditary (BRCA1, BRCA2 associated) and non-familial breast cancer: results of a prospective breast cancer family registry international population-based cohort study.
  [2073] Pharmacokinetics and tolerability of lapatinib administered once daily in combination with tamoxifen.
  [2074] Role of Src family members in breast cancer-dependent on site of phosphorylation.
  [2075] Multicentric/-focal vs. unifocal breast cancer: is the TNM-classification justified.
  [2076] Phosphorylated c-Src predicts clinical outcome in triple negative breast cancers.
  [2077] Survival differences among women with newly diagnosed stage IV and recurrent breast cancer.
  [2078] Clinical outcomes of patients with T1N0 breast cancers: how important are biological risk factors?
  [2079] Outcome of breast cancer in young women stratified by age at diagnosis: the younger, the worse? The Korean Breast Cancer Society registry program data.
  [2080] Time distributions and prognosis factors of breast cancer recurrence in different sites after operation.
  [2081] Analysis of the rate of missing data, the rate of discordance between readers, and the rate of site versus central discordance in clinical studies of recently approved breast cancer agents that have used blinded independent central review.
  [2082] Biology and prognosis by age of primary operable breast cancer.
  [2083] Triple negative breast cancers: comparative study of clinical features and overall survival in an Irish population.
  [2085] Triple negative breast cancer phenotypes: a comparison between symptomatic and screening patients.
  [2086] The black to white breast cancer incidence rate crossover.
  [2087] Molecular differences between the triple negative tumors of African-American women and white women.
  [2088] Differences in breast cancer subtype distribution exist among ethnic subgroups of Asian women in California.
  [2089] Molecular differences in triple negative breast cancer between race/ethnicities.
  [2090] Admixture mapping to identify breast cancer susceptibility loci in African American women.
  [2091] Disparate racial benefits of chemotherapy in breast cancer.
  [2092] Good news for a change: receipt of adjuvant chemotherapy in diverse populations.
  [2093] Triple negative status as a risk factor for the development of brain metastases in African American breast cancer patients.
  [2094] Male breast cancer in Chinese population – a ten year review.
  [2095] Role of phosphoserine phosphatase-like in breast disease in African American women.
  [2097] A retrospective review of demographics and stage of presentation in patients with ER/PR/Her2-neu receptor negative breast cancer.
  [2098] Telephone disclosure of BRCA1/2 test results? Opinions of recipients of BRCA1/2 testing.
  [2099] Communication of treatment goals in breast cancer: a comparison of perceptions of physicians, nurses and patients.

 
 

Poster Sessions | Support | FAQ | Privacy Policy

San Antonio Breast Cancer Symposium
7703 Floyd Curl Dr. Mail Code 8224
San Antonio, TX 78229 USA
http://www.sabcs.org
Technical Support • © 2010 Marathon Multimedia, a Learner’s Digest International business. • All rights reserved